Lerpin (Lercanidipine Hydrochloride)

Lercanidipine selectively inhibits L‑type calcium channels in arterial smooth‑muscle cells, decreasing calcium entry. This causes relaxation of the vascular smooth muscle, leading to vasodilation, reduced peripheral resistance, and ultimately a drop in systemic blood pressure.

The appropriate dose of Lerpin is determined by the prescribing healthcare professional based on the patient’s clinical condition, response to therapy, and any concomitant medications. Dosage adjustments may be needed for special populations.

The safety of lercanidipine in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified clinician.

To order Lerpin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lerpin belongs to the dihydropyridine calcium‑channel blocker class, which primarily causes arterial vasodilation. Compared with ACE inhibitors or ARBs, it has a lower incidence of cough but may cause more peripheral edema. Choice of therapy depends on patient comorbidities, tolerability, and physician preference.

Lerpin tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date printed on the packaging.

Lerpin is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and not alter the dose without medical advice.

Serious adverse events, although rare, include severe hypotension, angioedema, myocardial infarction, hepatic dysfunction, and cardiac conduction disturbances such as heart block. Patients should seek immediate medical attention if they experience symptoms like sudden dizziness, swelling of the face or throat, chest pain, or abnormal heart rhythms.

Lerpin is contraindicated in patients with known hypersensitivity to lercanidipine or any component of the formulation. It should also be avoided in individuals with severe aortic stenosis, unstable angina, or those taking strong CYP3A4 inhibitors without appropriate medical supervision.